Evidence map›Paper›PMID 41672381›Full record

ArticleBiochimica et biophysica acta. Molecular basis of disease2026

Novel VARS1 variants define new clinical and molecular subtypes of a rare neurodevelopmental syndrome.

Busra Aynekin, Tracy Lau, Rauan Kaiyrzhanov, Ioannis Papazoglou, Ayten Gulec, Ummu Gulsum Ozgul Gumus, Svetlena Gorokhova, Busa Tiffany, Leonardo Simão Medeiros, Ida Vanessa Doederlein Schwartz and 13 more

Erratum issuedAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Molecular basis of disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Busra AynekinDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK; Department of Molecular Biology and Genetics, Biruni University, 34015, Istanbul, Türkiye.
Tracy LauDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Rauan KaiyrzhanovDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Ioannis PapazoglouLaboratory for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahçeşehir University, 34734, İstanbul, Türkiye.
Ayten GulecDepartment of Pediatrics, Erciyes University, Faculty of Medicine, Kayseri, Turkey.
Ummu Gulsum Ozgul GumusDepartment of Pediatrics, Erciyes University, Faculty of Medicine, Kayseri, Turkey.
Svetlena GorokhovaDepartment of Medical Genetics, Timone Children's Hospital, APHM, Marseille, France.
Busa TiffanyDepartment of Medical Genetics, Timone Children's Hospital, APHM, Marseille, France.
Leonardo Simão MedeirosMedical Genetics Service-Hospital de Clinicas de Porto Alegre-Brazil, Porto Alegre, RS, Brazil.
Ida Vanessa Doederlein SchwartzMedical Genetics Service-Hospital de Clinicas de Porto Alegre-Brazil, Porto Alegre, RS, Brazil.
Mehmet Burak MutluDepartment of Medical Genetics, Detagen Genetic Diseases Evaluation Center, Kayseri, Türkiye.
Sofia OuraniClinical Genetics Department, Archbishop Makarios III Hospital, Nicosia, Cyprus.
Anke BergmanHannover Medical School, Institute of Human Genetics, Hannover, Germany.
Kelly SchochDivision of Medical Genetics, Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Huseyin PerDepartment of Pediatrics, Erciyes University, Faculty of Medicine, Kayseri, Turkey.
Nurdeniz Nalbant BingolDepartment of Translational Medicine, Institute of Health Sciences, Bursa Uludag University, Bursa, Türkiye.
Sehime G TemelDepartment of Translational Medicine, Institute of Health Sciences, Bursa Uludag University, Bursa, Türkiye; Department of Medical Genetics, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye; Department of Histology and Embryology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
Serdar DurdağıLaboratory for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahçeşehir University, 34734, İstanbul, Türkiye; Molecular Therapy Lab, Department of Pharmaceutical Chemistry, School of Pharmacy, Bahcesehir University, Istanbul, Türkiye; Systems Biology Lab, Biruni University Scientific Research Center, Biruni University, Istanbul, Türkiye. Electronic address: serdar.durdagi@bau.edu.tr.
Semra HızDepartment of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, Izmir, 35340, Turkey.
Geneviève BernardDepartment of Neurology and Neurosurgery, McGill University, Montreal, Canada; Departments of Pediatrics and Human Genetics, McGill University, Montreal, Canada; Child Health and Human Development Program, McGill University Health Centre Research Institute, Montreal, Canada; Department Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, Canada.
Felipe Villa TobonDepartment of Neurology and Neurosurgery, McGill University, Montreal, Canada.
Henry HouldenDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. Electronic address: h.houlden@ucl.ac.uk.
Stephanie EfthymiouDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. Electronic address: s.efthymiou@ucl.ac.uk.

Funding

Wellcome Trust
6 · The paper itself

Abstract

purposeWe aimed to broaden the understanding of autosomal recessive neurodevelopmental disorders caused by VARS1 by describing new clinical and molecular findings and assessing the predicted structural impact of identified variants.

methodsWe clinically evaluated 13 affected individuals from 10 unrelated families presenting with a neurodevelopmental disorder. We used exome sequencing and cosegregation analyses to identify disease-causing variants, followed by three-dimensional in silico analyses and molecular dynamics simulations to assess the likely functional consequences of both previously reported and novel variants.

resultsIn all affected individuals who presented with a neurodevelopmental syndrome with progressive microcephaly, seizures, and intellectual disability, we identified biallelic disease-causing variants in VARS1. Two variants were predicted to induce premature protein truncation leading to loss of VARS1 function. The remaining 13 detected missense variants were located in the catalytic and aminoacylation domains, and in silico analysis of the affected residues showed that such substitutions can disrupt local protein dynamics, RNA-interaction surfaces, or catalytic geometry, thereby affecting ligand recognition, substrate specificity, and tRNA interaction.

conclusionTogether with prior reports, our results provide strong additional evidence supporting VARS1 as a recurrent cause of autosomal recessive neurodevelopmental disorders and expand the known clinical and allelic spectrum. While in silico analyses provide mechanistic plausibility for novel variants, functional studies will be important to confirm variant-specific effects and disease mechanisms.

Indexed as

Amino Acyl-tRNA SynthetasesNeurodevelopmental DisordersAdolescentChildChild, PreschoolExome SequencingFemaleHumansInfantIntellectual DisabilityMaleMicrocephalyMolecular Dynamics SimulationMutation, MissensePedigreeSeizuresAmino Acyl-tRNA SynthetasesAminoacyl tRNA synthetaseMendelian disordersMolecular dynamicsMonogenic diseasesNeurodevelopment

Identifiers

PMID41672381
PMCPMC7619359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.